Leukotrienes: Mediators that have been typecast as villains

Cellular and Molecular Life Sciences

Volumn 64, Issue 19-20, 2007, Pages 2657-2670

  Flamand, N ^a   Mancuso, P ^b   Serezani, C H C ^a   Brock, T G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

5 lipoxygenase; Arachidonic acid; Atherosclerosis; Bronchoconstriction; Gene expression; Inflammation; Phagocytosis

Indexed keywords

LEUKOTRIENE;

ATHEROSCLEROSIS; BACTERIAL INFECTION; BRONCHOSPASM; CANCER; FATTY ACID SYNTHESIS; GENE EXPRESSION; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOSTIMULATION; INFLAMMATION; LUNG FIBROSIS; MEDIATOR; MYCOSIS; NONHUMAN; PHAGOCYTOSIS; PROTEIN FUNCTION; REVIEW; VIRUS INFECTION;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, NATURAL; INFLAMMATION MEDIATORS; LEUKOTRIENES;

BACTERIA (MICROORGANISMS);

EID: 35648958179     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-007-7228-2     Document Type: Review

References (179)

1. 4 but no peptidoleukotrienes. J. Immunol. 144, 1880-1885.
2. Henderson, R. F., Leung, H. W., Harmsen, A. G. and McClellan, R. O. (1988) Species differences in release of arachidonate metabolites in response to inhaled diluted diesel exhaust. Toxicol. Lett. 42, 325-332.
3. 4 that mediates chemotaxis. Nature 387, 620-624.
4. 11 G-protein subunits. Biochem. J. 335, 15-18.
5. Yokomizo, T., Kato, K., Terawaki, K., Izumi, T. and Shimizu, T. (2000) A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 192, 421-432.
6. Lin, Q., Ruuska, S. E., Shaw, N. S., Dong, D. and Noy, N. (1999) Ligand selectivity of the peroxisome proliferator-activated receptor alpha. Biochemistry 38, 185-190.
7. 4 pathway to inflammation control. Nature 384, 39-43.
8. Lynch, K. R., O'Neil, G. P., Liu, Q., Im, D. S., Sawyer, N., Metters, K. M., Coulombe, N., Abramovitz, M., Figueroa, D. J., Zeng, Z., Connolly, B. M., Bai, C., et al. (1999) Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399, 789-793.
9. Heise, C. E., O'Dowd, B. F., Figueroa, D. J., Sawyer, N., Nguyen, T., Im, D., Stocco, R., Bellefeuille, J. N., Abramovitz, M., Cheng, R., Williams, D. L., Zeng, Z. et al. (2000) Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 275, 30531-30536.
10. Ciana, P., Fumagalli, M., Trincavelli, M. L., Verderio, C., Rosa, P., Lecca, D., Ferrario, S., Parravicini, C., Capra, V., Gelosa, P., Guerrini, U., Belcredito, S. et al. (2006) The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 25, 4615-4627.
11. 4 stimulates polymorphonuclear leukocyte adhesion to cultured vascular endothelial cells. J. Clin. Invest. 74, 1552-1555.
12. 4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286, 264-265.
13. 4-stimulated leukocytes to lysosomal enzyme release and the generation of superoxide anions. Biochim. Biophys. Acta 804, 52-57.
14. Cunningham, F. M., Shipley, M. E. and Smith, M. J. (1980) Aggregation of rat polymorphonuclear leucocytes in vitro. J. Pharm. Pharmacol. 32, 377-380.
15. 4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 91, 837-844.
16. 4. Gut. 39, 248-254.
17. 4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86, 453-460.
18. 4 plays a critical role in the progression of collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 92, 517-521.
19. Klickstein, L. B., Shapleigh, C. and Goetzl, E. J. (1980) Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. J. Clin. Invest. 66, 1166-1170.
20. Ruzicka, T., Simmet, T., Peskar, B. A. and Ring, J. (1986) Skin levels of arachidonic acid-derived inflammatory mediators and histamine in atopic dermatitis and psoriasis. J. Invest. Dermatol. 86, 105-108.
21. Cromwell, W., Walport, M., Taylor, G. W., Morris, H. R., O'Driscoll, B. R. and Kay, A. B. (1981) Identification of leukotrienes D and B in sputum from cystic fibrosis patients. Lancet 2, 164-165.
22. Dahlen, S. E., Hedqvist, P., Hammarstrom, S. and Samuelsson, B. (1980) Leukotrienes are potent constrictors of human bronchi. Nature 288, 484-486.
23. Shelhamer, J., Marom, Z., Sun, F., Bach, M. and Kaliner, M. (1982) The effects of arachinoids and leukotrienes on the release of mucus from human airways. Chest 81, 36-37.
24. 4: a potent coronary artery vasoconstrictor associated with impaired ventricular contraction. Science 217, 841-843.
25. Schellenberg, R. R. and Foster, A. (1984) Differential activity of leukotrienes upon human pulmonary vein and artery. Prostaglandins 27, 475-482.
26. Drazen, J. M., Austen, K. F., Lewis, R. A., Clark, D. A., Goto, G., Marfat, A. and Corey, E. J. (1980) Comparative airway and vascular activity of leukotrienes C-1 and D in vivo and in vitro. Proc. Natl. Acad. Sci. USA 77, 4354-4358.
27. Dahlen, S. E., Bjork, J., Hedqvist, P., Arfors, K. E., Hammarstrom, S., Lindgren, J. A. and Samuelsson, B. (1981) Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc. Natl. Acad. Sci. USA 78, 3887-3891.
28. 3H]arachidonic acid in murine fibrosarcoma cells measured by electron microscope autoradiography. J. Cell Biol. 101, 573-581.
29. 4 synthetic capacity. Proc. Natl. Acad. Sci. USA 100, 12165-12170.
30. 2. Nature 390, 622-625.
31. 2 in macrophages in response to bacteria. Eur. J. Biochem. 213, 81-86.
32. 2 phosphorylation and eicosanoid production by colony-stimulating factor 1. J. Biol. Chem. 269, 31693-31700.
33. 2 in human platelets. J. Biol. Chem. 268, 26795-26804.
34. 2(s) by transforming growth factor-beta. Biochim. Biophys. Acta 1256, 201-209.
35. Brock, T. G., McNish, R. W., Coffey, M. J., Ojo, T. C., Phare, S. M. and Peters-Golden, M. (1996) Effect of granulocyte-macrophage colony-stimulating factor on eicosanoid production by mononuclear phagocytes. J. Immunol. 156, 2522-2527.
36. 2. EMBO J. 11, 4917-4922.
37. 2γ) protein expression. Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L497-502.
38. 2-independent cysteinyl leukotriene synthesis in human eosinophils. J. Biol. Chem. 278, 38813-38820.
39. 2 by guinea pig alveolar macrophages. J. Immunol. 151, 5613-5623.
40. 2 mRNA synthesis in rabbit articular chondrocytes. Biochem. Biophys. Res. Commun. 164, 488-495.
41. Folco, G. and Murphy, R. C. (2006) Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol. Rev. 58, 375-388.
42. Needleman, P., Turk, J., Jakschik, B. A., Morrison, A. R. and Lefkowith, J. B. (1986) Arachidonic acid metabolism. Annu. Rev. Biochem. 55, 69-102.
43. 4. J. Biol. Chem. 264, 19469-19472.
44. Radmark, O. and Samuelsson, B. (2005) Regulation of 5-lipoxygenase enzyme activity. Biochem. Biophys. Res. Commun. 338, 102-110.
45. Luo, M., Flamand, N. and Brock, T. G. (2006) Metabolism of arachidonic acid to eicosanoids within the nucleus. Biochim. Biophys. Acta 1761, 618-625.
46. 4 in the urine, and bronchial provocation with lysine-aspirin results in further release. Am. Rev. Respir. Dis. 143, 599.
47. Wilborn, J., Bailie, M., Coffey, M., Burdick, M., Strieter, R. and Peters-Golden, M. (1996) Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Invest. 97, 1827-1836.
48. Moody, T. W., Leyton, J., Martínez, A., Hong, S., Malkinson, A. and Mulshine, J. L. (1998) Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp. Lung Res. 24, 617-628.
49. Avis, I. M., Jett, M., Boyle, T., Vos, M. D., Moody, T., Treston, A. M., Martínez, A. and Mulshine, J. L. (1996) Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J. Clin. Invest. 97, 806-813.
50. 4 receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am. J. Pathol. 161, 421-428.
51. Yoshimura, R., Matsuyama, M., Tsuchida, K., Kawahito, Y., Sano, H and Nakatani, T. (2003) Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. J. Urol. 170, 1994-1999.
52. Ghosh, J. (2003) Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. Biochem. Biophys. Res. Commun. 307, 342-349.
53. Matsuyama, M., Yoshimura, R., Mitsuhashi, M., Tsuchida, K., Takemoto, Y., Kawahito, Y., Sano, H. and Nakatani, T. (2005) 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol. Rep. 14, 73-79.
54. Hoque, A., Lippman, S. M., Wu, T. T., Xu, Y., Liang, Z. D., Swisher, S., Zhang, H., Cao, L., Ajani, J. A. and Xu, X. C. (2005) Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 26, 785-791.
55. Soumaoro, L. T., Iida, S., Uetake, H., Ishiguro, M., Takagi, Y., Higuchi, T., Yasuno, M., Enomoto, M. and Sugihara, K. (2006) Expression of 5-lipoxygenase in human colorectal cancer. World J. Gastroenterol. 12, 6355-6360.
56. Chen, X., Sheller, J., Johnson, E. and Funk, C. (1994) Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372, 179-182.
57. Goulet, J., Snouwaert, J., Latour, A., Coffman, T. and Koller, B. (1994) Altered inflammatory responses in leukotriene-deficient mice. Proc. Natl. Acad. Sci. USA 91, 12852-12856.
58. Byrum, R. S., Goulet, J. L., Griffiths, R. J. and Koller, B. H. (1997) Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. J. Exp. Med. 185, 1065-1075.
59. Griffiths, R. J., Smith, M. A., Roach, M. L., Stock, J. L., Stam, E. J., Milici, A. J., Scampoli, D. N., Eskra, J. D., Byrum, R. S., Koller, B. H. and McNeish, J. D. (1997) Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice. J. Exp. Med. 185, 1123-1129.
60. 4 is required for inflammatory arthritis. J. Exp. Med. 203, 837-842.
61. Shim, Y. M., Zhu, Z., Zheng, T., Lee, C. G., Homer, R. J., Ma, B. and Elias, J. A. (2006) Role of 5-lipoxygenase in IL-13-induced pulmonary inflammation and remodeling. J. Immunol. 177, 1918-1924.
62. Cuzzocrea, S., Rossi, A., Serraino, I., Di Paola, R., Dugo, L., Genovese, T., Britti, D., Sciarra, G., De Sarro, A., Caputi, A. and Sautebin, L. (2003) 5-Lipoxygenase knockout mice exhibit a resistance to acute pancreatitis induced by cerulein. Immunology 110, 120-130.
63. Voelkel, N. F., Tuder, R. M., Wade, K., Hoper, M., Lepley, R. A., Goulet, J. L., Koller, B. H. and Fitzpatrick, F. (1996) Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J. Clin. Invest. 97, 2491-2498.
64. Irvin, C. G., Tu, U. P., Sheller, J. R. and Funk, C. D. (1997) 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am. J. Physiol. 272, L1053-L1058.
65. Goulet, J. L., Griffiths, R. C., Ruiz, P., Spurney, R. F., Pisetsky, D. S., Koller, B. H. and Coffman, T. M. (1999) Deficiency of 5-lipoxygenase abolishes sex-related survival differences in MRL-lpr/lpr mice. J. Immunol. 163, 359-366.
66. Goulet, J. L., Griffiths, R. C., Ruiz, P., Mannon, R. B., Flannery, P., Platt, J. L., Koller, B. H. and Coffman, T. M. (2001) Deficiency of 5-lipoxygenase accelerates renal allograft rejection in mice. J. Immunol. 167, 6631-6636.
67. Peters-Golden, M., Bailie, M., Marshall, T., Wilke, C., Phan, S. H., Toews, G. B. and Moore, B. B. (2002) Protection from pulmonary fibrosis in leukotriene-deficient mice. Am. J. Respir. Crit. Care Med. 165, 229-235.
68. Cuzzocrea, S., Rossi, A., Serraino, I., Di Paolo, R., Dugo, L., Genovese, T., Caputi, A. and Sautebin, L. (2003) 5-Lipoxygenase knockout mice exhibit a resistance to splanchnic artery occlusion shock. Shock 20, 230-236.
69. Patel, N., Cuzzocrea, S., Chatterjee, P., Di Paola, R., Sautebin, L., Britti, D. and Thiemermann, C. (2004) Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. Mol. Pharmacol. 66, 220-227.
70. 4 hydrolase-deficient mice. J. Immunol. 163, 6810-6819.
71. 4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J. Exp. Med. 203, 829-835.
72. 4 receptors BLT1 and BLT2: a critical role for BLT1 in collagen-induced arthritis in mice. J. Immunol. 176, 6254-6261.
73. Beller, T. C., Friend, D. S., Maekawa, A., Lam, B. K., Austen, K. F. and Kanaoka, Y. (2004) Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc. Natl. Acad. Sci. USA 101, 3047-3052.
74. Beller, T. C., Maekawa, A., Friend, D. S., Austen, K. F. and Kanaoka, Y. (2004) Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J. Biol. Chem. 279, 46129-46134.
75. Mehrabian, M., Allayee, H., Wong, J., Shih, W., Wang, X. P., Shaposhnik, Z., Funk, C. D. and Lusis, A. J. (2002) Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res. 91, 120-126.
76. Spanbroek, R., Grabner, R., Lotzer, K., Hildner, M., Urbach, A., Ruhling, K., Moos, M. P., Kaiser, B., Cohnert, T. U., Wahlers, T., Zieske, A., Plenz, G. et al. (2003) Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. USA 100, 1238-1243.
77. 4 and BLT1 in smooth muscle cell recruitment. Circulation 112, 578-586.
78. 4 signaling through NF-κB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc. Natl. Acad. Sci. USA 102, 17501-17506.
79. 4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc. Natl. Acad. Sci. USA 103, 8161-8166.
80. Uzonyi, B., Lotzer, K., Jahn, S., Kramer, C., Hildner, M., Bretschneider, E., Radke, D., Beer, M., Vollandt, R., Evans, J. F., Funk, C. D. and Habenicht, A. J. (2006) Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. Proc. Natl. Acad. Sci. USA 103, 6326-6331.
81. Woszczek, G., Chen, L., Nagineni, S., Alsaaty, S., Harry, A., Logun, C., Pawliczak, R. and Shelhamer, J. H. (2007) IFN-γ induces cysteinyl leukotriene receptor 2 expression and enhances the responsiveness of human endothelial cells to cysteinyl leukotrienes. J. Immunol. 178, 5262-5270.
82. Funk, C. D. (2005) Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat. Rev. Drug Discov. 4, 664-682.
83. Lotzer, K., Funk, C. D. and Habenicht, A. J. (2005) The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. Biochim. Biophys. Acta 1736, 30-37.
84. Radmark, O. and Samuelsson, B. (2007) 5-Lipoxygenase: Regulation and possible involvement in atherosclerosis. Prostaglandins Other Lipid Mediat. 83, 162-174.
85. Skerrett, S. J., Henderson, W. R. and Martin, T. R. (1990) Alveolar macrophage function in rats with severe protein calorie malnutrition: arachidonic acid metabolism, cytokine release, and antimicrobial activity. J. Immunol. 144, 1052-1061.
86. 4 generation in granulocytes from protein-energy malnourished chronically ill elderly. J. Intern. Med. 247, 715-722.
87. Anstead, G. M., Chandrasekar, B., Zhang, Q. and Melby, P. C. (2003) Multinutrient undernutrition dysregulates the resident macrophage proinflammatory cytokine network, nuclear factor-κB activation, and nitric oxide production. J. Leukoc. Biol. 74, 982-992.
88. Mancuso, P., Huffnagle, G. B., Olszewski, M. A., Phipps, J. and Peters-Golden, M. (2006) Leptin corrects host defense defects following acute starvation in murine pneumococcal pneumonia. Am. J. Respir. Crit. Care Med. 173, 212-218.
89. 4 synthesis in smokers' alveolar macrophages in vitro. J. Clin. Invest. 77, 54-60.
90. Balter, M. S., Toews, G. B. and Peters-Golden, M. (1989) Multiple defects in arachidonate metabolism in alveolar macrophages from young asymptomatic smokers. J. Lab. Clin. Med. 114, 662-673.
91. Coffey, M. J., Wilcoxen, S. E., Phare, S. M., Simpson, R. U., Gyetko, M. R. and Peters-Golden, M. (1994) Reduced 5-lipoxygenase metabolism of arachidonic acid in macrophages from 1,25-dihydroxyvitamin D3-deficient rats. Prostaglandins 48, 313-329.
92. Coffey, M., Phare, S. M., Kazanjian, P. H. and Peters-Golden, M. (1996) 5-Lipoxygenase metabolism in alveolar macrophages from subjects infected with the human immunodeficiency virus. J. Immunol. 157, 393-399.
93. 4 are absent in the cerebrospinal fluid of human immunodeficiency virus type 1-seropositive persons with toxoplasmic encephalitis: evidence for inhibition of 5-lipoxygenase by Toxoplasma gondii. J. Infect. Dis. 179, 714-716.
94. Claria, J., Titos, E., Jimenez, W., Ros, J., Gines, P., Arroyo, V., Rivera, F. and Rodes, J. (1998) Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. Gastroenterology 115, 147-156.
95. 4 synthesis by polymorphonuclear leukocytes from male patients with diabetes mellitus. Prostaglandins Leukot. Med. 14, 305-311.
96. Peters-Golden, M., Canetti, C., Mancuso, P. and Coffey, M. J. (2005) Leukotrienes: Underappreciated mediators of innate immune responses. J. Immunol. 174, 589-594.
97. Bailie, M. B., Standiford, T. J., Laichalk, L. L., Coffey, M. J., Strieter, R. and Peters-Golden, M. (1996) Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. J. Immunol. 157, 5221-5224.
98. Malaviya, R. and Abraham, S. N. (2000) Role of mast cell leukotrienes in neutrophil recruitment and bacterial clearance in infectious peritonitis. J. Leukoc. Biol. 67, 841-846.
99. Benjamim, C. F., Canetti, C., Cunha, F. Q., Kunkel, S. L. and Peters-Golden, M. (2005) Opposing and hierarchical roles of leukotrienes in local innate immune versus vascular responses in a model of sepsis. J. Immunol. 174, 1616-1620.
100. Bafica, A., Scanga, C. A., Serhan, C., Machado, F., White, S., Sher, A. and Aliberti, J. (2005) Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J. Clin. Invest. 115, 1601-1606.
101. Peres, C., de Paula, L., Medeiros, A., Sorgi, C., Soares, E., Carlos, D., Peters-Golden, M., Silva, C. and Faccioli, L. (2007) Inhibition of leukotriene biosynthesis abrogates the host control of Mycobacterium tuberculosis. Microbes Infect. 9, 483-489.
102. Medeiros, A. I., Sa-Nunes, A., Soares, E. G., Peres, C. M., Silva, C. L. and Faccioli, L. H. (2004) Blockade of endogenous leukotrienes exacerbates pulmonary Histoplasmosis. Infect. Immun. 72, 1637-1644.
103. 4 protects latently infected mice against murine cytomegalovirus reactivation following allogeneic transplantation. J. Immunol. 174, 1587-1593.
104. Chen, N., Restivo, A. and Reiss, C. S. (2001) Leukotrienes play protective roles early during experimental VSV encephalitis. J. Neuroimmunol. 120, 94-102.
105. Serezani, C. H., Perrela, J. H., Russo, M., Peters-Golden, M. and Jancar, S. (2006) Leukotrienes are essential for the control of Leishmania amazonensis infection and contribute to strain variation in susceptibility. J. Immunol. 177, 3201-3208.
106. Claesson, H., Lindgren, J. and Gustafsson, B. (1985) Opsonized bacteria stimulate leukotriene synthesis in human leukocytes. Biochim. Biophys. Acta 836, 361-367.
107. Mancuso, P., Standiford, T., Marshall, T. and Peters-Golden, M. (1998) 5-Lipoxygenase reaction products modulate alveolar macrophage phagocytosis of Klebsiella pneumoniae. Infect. Immun. 66, 5140-5146.
108. McCurdy, J. D., Olynych, T. J., Maher, L. H. and Marshall, J. S. (2003) Cutting edge: Distinct toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J. Immunol. 170, 1625-1629.
109. Surette, M. E., Palmantier, R., Gosselin, J. and Borgeat, P. (1993) Lipopolysaccharides prime whole human blood and isolated neutrophils for the increased synthesis of 5-lipoxygenase products by enhancing arachidonic acid availability: involvement of the CD14 antigen. J. Exp. Med. 178, 1347-1355.
110. 2 and platelet-activating factor biosynthesis. FASEB J. 21, 1575-1585.
111. Olsson, S. and Sundler, R. (2007) The macrophage beta-glucan receptor mediates arachidonate release induced by zymosan: essential role for Src family kinases. Mol. Immunol. 44, 1509-1515.
112. Mancuso, P., Gottschalk, A., Phare, S. M., Peters-Golden, M., Lukacs, N. W. and Huffnagle, G. B. (2002) Leptin-deficient mice exhibit impaired host defense in gram-negative pneumonia. J. Immunol. 168, 4018-4024.
113. Coffey, M. J., Phare, S. M. and Peters-Golden, M. (2004) Role of leukotrienes in killing of Mycobacterium bovis by neutrophils. Prostaglandins Leukot. Essent. Fatty Acids 71, 185-190.
114. Castro, M., Morgenthaler, T. I., Hoffman, O. A., Standing, J. E., Rohrbach, M. S. and Limper, A. H. (1993) Pneumocystis carinii induces the release of arachidonic acid and its metabolites from alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 9, 73-81.
115. Wolf, J. E., Massof, S. E. and Peters, S. P. (1992) Alterations in murine macrophage arachidonic acid metabolism following ingestion of nonviable Histoplasma capsulatum. Infect. Immun. 60, 2559-2564.
116. Gosselin, J. and Borgeat, P. (1997) Epstein-Barr virus modulates 5-lipoxygenase product synthesis in human peripheral blood mononuclear cells. Blood 89, 2122-2130.
117. 4. J. Immunol. 163, 6148-6154.
118. Zimmerman, B. J., Holt, J. W., Paulson, J. C., Anderson, D. C., Miyasaka, M., Tamatani, T., Todd, R. F., Rusche, J. R. and Granger, D. N. (1994) Molecular determinants of lipid mediator-induced leukocyte adherence and emigration in rat mesenteric venules. Am. J. Physiol. 266, H847-H853.
119. 4 receptor BLT1 mediates early effector T cell recruitment. Nat. Immunol. 4, 982-990.
120. 4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood 107, 444-453.
121. 4. Nat. Immunol. 4, 974-981.
122. Prinz, I., Gregoire, C., Mollenkopf, H., Aguado, E., Wang, Y., Malissen, M., Kaufmann, S. H. and Malissen, B. (2005) The type 1 cysteinyl leukotriene receptor triggers calcium influx and chemotaxis in mouse αβ- and γδ-effector T cells. J. Immunol. 175, 713-719.
123. Doepping, S., Funk, C. D., Habenicht, A. J. and Spanbroek, R. (2007) Selective 5-lipoxygenase expression in Langerhans cells and impaired dendritic cell migration in 5-LO-deficient mice reveal leukotriene action in skin. J. Invest. Dermatol. 127, 1692-1700.
124. Hebert, M. J., Takano, T., Holthofer, H. and Brady, H. R. (1996) Sequential morphologic events during apoptosis of human neutrophils. Modulation by lipoxygenase-derived eicosanoids. J. Immunol. 157, 3105-3115.
125. Lee, E., Robertson, T., Smith, J. and Kilfeather, S. (2000) Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am. J. Respir. Crit. Care Med. 161, 1881-1886.
126. 4 on macrophage association with and intracellular destruction of Trypanosoma cruzi. J. Immunol. 134, 1989-1993.
127. 4 on macrophage association with and intracellular fate of Trypanosoma cruzi. Mol. Biochem. Parasitol. 15, 1-10.
128. 4. Int. J. Immunopharmacol. 11, 801-808.
129. Mancuso, P. and Peters-Golden, M. (2000) Modulation of alveolar macrophage phagocytosis by leukotrienes is Fc receptor-mediated and protein kinase C-dependent. Am. J. Respir. Cell. Mol. Biol. 23, 727-732.
130. 4 augments neutrophil phagocytosis of Klebsiella pneumoniae. Infect. Immun. 69, 2011-2016.
131. 4-regulated event involved in macrophage phagocytosis of IgG-coated targets but not apoptotic cells. Blood 102, 1877-1883.
132. 4 receptor antagonist. Biochem. Pharmacol. 49, 1683-1690.
133. Serezani, C. H. C., Aronoff, D. M., Jancar, S., Mancuso, P. and Peters-Golden, M. (2005) Leukotrienes enhance the bactericidal activity of alveolar macrophages against Klebsiella pneumoniae through the activation of NADPH oxidase. Blood 106, 1067-1075.
134. 4 induces nitric oxide synthesis in Trypanosoma cruzi-infected murine macrophages and mediates resistance to infection. Infect. Immun. 70, 4247-4253.
135. Yong, E. C., Chi, E. Y. and Henderson, W. R. J. (1994) Toxoplasma gondii alters eicosanoid release by human mononuclear phagocytes: role of leukotrienes in interferon gamma-induced antitoxoplasma activity. J. Exp. Med. 180, 1637-1648.
136. Coffey, M. J., Phare, S. M., George, S., Peters-Golden, M. and Kazanjian, P. H. (1998) Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. J. Clin. Invest. 102, 663-670.
137. 4. Clin. Exp. Immunol. 52, 519-527.
138. 4 is a complete secretagogue in human neutrophils: A kinetic analysis. Biochem. Biophys. Res. Commun. 107, 1006-1012.
139. 4 to humans. J. Infect. Dis. 189, 2001-2009.
140. 4. Biochem. Biophys. Res. Commun. 128, 297-304.
141. 4 in human polymorphonuclear leukocytes. Blood 93, 1399-1405.
142. Bandeira-Melo, C., Hall, J. C., Penrose, J. F. and Weller, P. F. (2002) Cysteinyl leukotrienes induce IL-4 release from cord blood-derived human eosinophils. J. Allergy Clin. Immunol. 109, 975-979.
143. Bandeira-Melo, C., Woods, L. J., Phoofolo, M. and Weller, P. F. (2002) Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. J. Exp. Med. 196, 841-850.
144. 4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses. FASEB J. [Epub ahead of print].
145. 4 transcriptionally activates interleukin-6 expression involving NK-chi B and NF-IL6. Eur. J. Immunol. 22, 2705-2711.
146. 4 up-regulates IL-6 rather than IL-1 synthesis in human monocytes. Agents Actions 34, 42-45.
147. Thompson, C., Cloutier, A., Bosse, Y., Thivierge, M., CL, G., Larivee, P., McDonald, P., Stankova, J. and Rola-Pleszczynski, M. (2006) CysLT1 receptor engagement induces activator protein-1- and NF-κB-dependent IL-8 expression. Am. J. Respir. Cell Mol. Biol. 35, 697-704.
148. Lötzer, K., Jahn, S., Kramer, C., Hildner, M., Nüsing, R., Funk, C. D. and Habenicht, A. J. R. (2007) 5-Lipoxygenase/ cyclooxygenase-2 cross-talk through cysteinyl leukotriene receptor 2 in endothelial cells. Prostaglandins Other Lipid Mediat. doi:10.1016/j.prostaglandins.2007.04.005.
149. 4 in up-regulation of CCR7 expression and function. Blood 109, 626-631.
150. Thivierge, M., Stankova, J. and Rola-Pleszczynski, M. (2006) Toll-like receptor agonists differentially regulate cysteinyl-leukotriene receptor 1 expression and function in human dendritic cells. J. Allergy Clin. Immunol. 117, 1155-1162.
151. Ichiyama, T., Kajimoto, M., Hasegawa, M., Hashimoto, K., Matsubara, T. and Furukawa, S. (2007) Cysteinyl leukotrienes enhance tumour necrosis factor-alpha-induced matrix metalloproteinase-9 in human monocytes/macrophages. Clin. Exp. Allergy 37, 608-614.
152. 4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes. Biochem. J. 282, 625-629.
153. 4. Proc. Natl. Acad. Sci. USA 103, 6913-6918.
154. Vaddi, K. and Newton, R. C. (1994) Regulation of monocyte integrin expression by beta-family chemokines. J. Immunol. 153, 4721-4732.
155. 4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells. Blood 105, 1274-1279.
156. 4 in the interleukin-4-induced human mononuclear phagocyte activation. Immunology 88, 384-388.
157. 4 enhances IL-4-induced IgE production from normal human lymphocytes. Cell. Immunol. 156, 124-134.
158. 4) on BALB/c mice splenocyte production of Th1 and Th2 lymphokines. Int. J. Immunopharmacol. 17, 457-463.
159. Dokter, W. H., Sierdsema, S. J., Esselink, M. T., Halie, M. R. and Vellenga, E. (1994) Interleukin-4-mediated inhibition of C-Fos mRNA expression: role of the lipoxygenase directed pathway. Leukemia 8, 1181-1184.
160. 4 involvement in cutaneous leishmaniasis: relation with infection status and cytokine production. Parasitology 112, 13-19.
161. 4. Immunology 91, 369-374.
162. 4 augments interleukin-2 receptor-beta (IL-2R beta) expression and IL-2R beta-mediated cytotoxic response in human peripheral blood lymphocytes. Immunology 76, 258-263.
163. 4 enhances their sensitivity in IL-2-driven tumor necrosis factor-α production: Transcriptional and post-transcriptional up-regulation of IL-2 receptors. J. Immunol. 150, 4041-4051.
164. 4 induces interleukin 5 generation from human T lymphocytes. Eur. J. Immunol. 23, 2392-2398.
165. 4. J. Immunol. 167, 2869-2878.
166. 4 mediates histamine induction of NF-κB and IL-8 in human bronchial epithelial cells. Am. J. Physiol. 274, L1030-L1039.
167. 4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler. Thromb. Vasc. Biol. 24, 1783-1788.
168. 4 induces brain edema and enhances CysLT2 receptor-mediated aquaporin 4 expression. Biochem. Biophys. Res. Commun. 350, 399-404.
169. 4-induced proliferation in colon cancer cells. Carcinogenesis 26, 1988-1998.
170. Lee, K. S., Kim, S. R., Park, H. S., Park, S. J., Min, K. H., Lee, K. Y., Jin, S. M. and Lee, Y. C. (2007) Cysteinyl leukotriene upregulates IL-11 expression in allergic airway disease of mice. J. Allergy Clin. Immunol. 119, 141-149.
171. 4 enhances immunoglobulin production in CD40-activated human B lymphocytes. J. Allergy Clin. Immunol. 117, 924-930.
172. Mellor, E. A., Austen, K. F. and Boyce, J. A. (2002) Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J. Exp. Med. 195, 583-592.
173. Mellor, E. A., Frank, N., Soler, D., Hodge, M. R., Lora, J. M., Austen, K. F. and Boyce, J. A. (2003) Expression of the type 2 receptor for cysteinyl leukotrienes CysLT2R by human mast cells: Functional distinction from CysLT1R. Proc. Natl. Acad. Sci. USA 100, 11589-11593.
174. Machida, I., Matsuse, H., Kondo, Y., Kawano, T., Saeki, S., Tomari, S., Obase, Y., Fukushima, C. and Kohno, S. (2004) Cysteinyl leukotrienes regulate dendritic cell functions in a murine model of asthma. J. Immunol. 172, 1833-1838.
175. 4 : potentiation of inflammation. Am. J. Respir. Cell Mol. Biol. 23, 572-577.
176. Wong, G. W., Foster, P. S., Yasuda, S., Qi, J. C., Mahalingam, S., Mellor, E. A., Katsoulotos, G., Li, L., Boyce, J. A., Krilis, S. A. and Stevens, R. L. (2002) Biochemical and functional characterization of human transmembrane tryptase TMT / tryptase gamma TMT is an exocytosed mast cell protease that induces airway hyperresponsiveness in vivo via an interleukin-13/ interleukin-4 receptor a/signal transducer and activator of transcription STAT 6-dependent pathway. J. Biol. Chem. 277, 41906-41915.
177. Shraga-Levine, Z., Ben-Menahem, D. and Naor, Z. (1996) Arachidonic acid and lipoxygenase products stimulate protein kinase Cβ mRNA levels in pituitary alpha T3 - 1 cell line: role in gonadotropin-releasing hormone action. Biochem. J. 316, 667-670.
178. Kawano, T., Matsuse, H., Kondo, Y., Machida, I., Saeki, S., Tomari, S., Mitsuta, K., Obase, Y., Fukushima, C., Shimoda, T. and Kohno, S. (2003) Cysteinyl leukotrienes induce nuclear factor kappa b activation and RANTES production in a murine model of asthma. J. Allergy Clin. Immunol. 112, 369-374.
179. 4 induces TGF-β1 production in airway epithelium via p38 kinase pathway. Am. J. Respir. Cell Mol. Biol. 34, 101-107.